G. Shaker, Reem Emam, Refka Messiha, H. A. Abdel-Moneim
{"title":"促红细胞生成素对1型糖尿病大鼠比目鱼肌代谢和收缩功能的影响。","authors":"G. Shaker, Reem Emam, Refka Messiha, H. A. Abdel-Moneim","doi":"10.21608/BESPS.2018.8209","DOIUrl":null,"url":null,"abstract":"Diabetes mellitus has been linked with specific morphological and metabolic abnormalities in skeletal muscle in a fiber specific manner. Erythropoietin (EPO) is a glycoprotein hormone that regulates the development of erythrocytes through binding to a high affinity receptor expressed in erythroid progenitor cells.EPO receptor expression in non-hematopoietic tissue, including skeletal muscle progenitor cells, raises the possibility of a role for EPO beyond erythropoiesis. So the aim of the present study was to evaluate the effect of EPO on skeletal muscle changes as a complication of type 1 diabetes mellitus in STZ- rat experimental model. Methods: 40 male Sprague Dawely rats were divided into 5 groups: control group , diabetic group (STZ-induced , 50 mg/kg I.P.), insulin treated diabetic ; (received 0.75 IU/ 100g body weight daily, S.C; for 4 weeks) , EPO treated diabetic; (received EPIAO® S.C , 200 I.U/Kg, 3 times weekly, day after day for 4 weeks),and insulin and EPO treated diabetic groups. At the end of the experiments, fasting blood glucose, insulin levels, lipid profile, contractile changes in soleus muscle and glucose transporter 4 (GLUT4) expression in soleus muscle were evaluated. Results: All biochemical parameters were improved in the group treated with insulin or EPO with greater improvement in insulin treated group. The greatest improvement was in the group treated with combined insulin and EPO. Contractile function of soleus muscle in diabetic group showed significant decrease in muscle tension either before or after fatigue, significant decrease in time taken to reach complete fatigue, significant increase in time taken to reach peak and in time taken to relax to 50% when compared with normal group. All parameters were improved in insulin treated and EPO treated groups, with greater improvement in insulin treated group. The greatest improvement was in combined insulin and EPO treated group. The reduced GLUT 4 expression in diabetic soleus muscle was significantly increased in insulin treated group as compared to EPO treated group, however combined EPO and insulin treated group showed greater increase in GLUT4 expression. Conclusion: The present results showed that, EPO injection improved hyperglycemia, hypoinsulinemia, hyperlipidemia, and skeletal muscle changes observed in STZ-induced diabetes in rats. Therefore, EPO could be beneficial in managing diabetic disorders and the application of EPO in treatment of diabetes can be considered.","PeriodicalId":9347,"journal":{"name":"Bulletin of Egyptian Society for Physiological Sciences","volume":"10 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2018-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effect of Erythropoietin on Metabolic and Contractile Functions of Soleus Muscle in Type I Diabetic Rats.\",\"authors\":\"G. Shaker, Reem Emam, Refka Messiha, H. A. Abdel-Moneim\",\"doi\":\"10.21608/BESPS.2018.8209\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Diabetes mellitus has been linked with specific morphological and metabolic abnormalities in skeletal muscle in a fiber specific manner. Erythropoietin (EPO) is a glycoprotein hormone that regulates the development of erythrocytes through binding to a high affinity receptor expressed in erythroid progenitor cells.EPO receptor expression in non-hematopoietic tissue, including skeletal muscle progenitor cells, raises the possibility of a role for EPO beyond erythropoiesis. So the aim of the present study was to evaluate the effect of EPO on skeletal muscle changes as a complication of type 1 diabetes mellitus in STZ- rat experimental model. Methods: 40 male Sprague Dawely rats were divided into 5 groups: control group , diabetic group (STZ-induced , 50 mg/kg I.P.), insulin treated diabetic ; (received 0.75 IU/ 100g body weight daily, S.C; for 4 weeks) , EPO treated diabetic; (received EPIAO® S.C , 200 I.U/Kg, 3 times weekly, day after day for 4 weeks),and insulin and EPO treated diabetic groups. At the end of the experiments, fasting blood glucose, insulin levels, lipid profile, contractile changes in soleus muscle and glucose transporter 4 (GLUT4) expression in soleus muscle were evaluated. Results: All biochemical parameters were improved in the group treated with insulin or EPO with greater improvement in insulin treated group. The greatest improvement was in the group treated with combined insulin and EPO. Contractile function of soleus muscle in diabetic group showed significant decrease in muscle tension either before or after fatigue, significant decrease in time taken to reach complete fatigue, significant increase in time taken to reach peak and in time taken to relax to 50% when compared with normal group. All parameters were improved in insulin treated and EPO treated groups, with greater improvement in insulin treated group. The greatest improvement was in combined insulin and EPO treated group. The reduced GLUT 4 expression in diabetic soleus muscle was significantly increased in insulin treated group as compared to EPO treated group, however combined EPO and insulin treated group showed greater increase in GLUT4 expression. Conclusion: The present results showed that, EPO injection improved hyperglycemia, hypoinsulinemia, hyperlipidemia, and skeletal muscle changes observed in STZ-induced diabetes in rats. Therefore, EPO could be beneficial in managing diabetic disorders and the application of EPO in treatment of diabetes can be considered.\",\"PeriodicalId\":9347,\"journal\":{\"name\":\"Bulletin of Egyptian Society for Physiological Sciences\",\"volume\":\"10 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Bulletin of Egyptian Society for Physiological Sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.21608/BESPS.2018.8209\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bulletin of Egyptian Society for Physiological Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21608/BESPS.2018.8209","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
糖尿病与骨骼肌纤维特异性形态和代谢异常有关。促红细胞生成素(EPO)是一种糖蛋白激素,通过与红细胞祖细胞中表达的高亲和力受体结合来调节红细胞的发育。EPO受体在非造血组织中的表达,包括骨骼肌祖细胞,增加了EPO在红细胞生成之外的作用的可能性。因此,本研究旨在探讨促生成素(EPO)对STZ-大鼠1型糖尿病并发骨骼肌变化的影响。方法:40只雄性Sprague Dawely大鼠分为5组:对照组、糖尿病组(stz诱导,50 mg/kg I.P.)、胰岛素治疗糖尿病;(每日摄入0.75 IU/ 100g体重,S.C;4周),EPO治疗糖尿病;(给予EPIAO®S.C, 200 iu /Kg,每周3次,日复一日,4周),胰岛素和促生成素治疗糖尿病组。实验结束时,测定各组大鼠空腹血糖、胰岛素水平、血脂、比目鱼肌收缩变化及比目鱼肌葡萄糖转运蛋白4 (GLUT4)表达。结果:胰岛素组和促生成素组各项生化指标均有改善,胰岛素组改善更大。胰岛素和促生成素联合治疗组改善最大。糖尿病组比目鱼肌收缩功能在疲劳前后肌肉张力均明显降低,达到完全疲劳所需时间明显缩短,达到峰值所需时间和放松所需时间均明显增加至正常组的50%。胰岛素治疗组和促生成素治疗组各项指标均有改善,其中胰岛素治疗组改善更大。以胰岛素与促生成素联合治疗组改善最大。胰岛素治疗组与促生成素治疗组相比,GLUT4在糖尿病比目鱼肌中的表达明显升高,而促生成素与胰岛素联合治疗组GLUT4的表达升高幅度更大。结论:本研究结果显示,注射EPO可改善stz诱导的糖尿病大鼠高血糖、低胰岛素血症、高脂血症及骨骼肌的改变。因此,促生成素可能有利于糖尿病疾病的控制,可考虑将促生成素应用于糖尿病的治疗。
Effect of Erythropoietin on Metabolic and Contractile Functions of Soleus Muscle in Type I Diabetic Rats.
Diabetes mellitus has been linked with specific morphological and metabolic abnormalities in skeletal muscle in a fiber specific manner. Erythropoietin (EPO) is a glycoprotein hormone that regulates the development of erythrocytes through binding to a high affinity receptor expressed in erythroid progenitor cells.EPO receptor expression in non-hematopoietic tissue, including skeletal muscle progenitor cells, raises the possibility of a role for EPO beyond erythropoiesis. So the aim of the present study was to evaluate the effect of EPO on skeletal muscle changes as a complication of type 1 diabetes mellitus in STZ- rat experimental model. Methods: 40 male Sprague Dawely rats were divided into 5 groups: control group , diabetic group (STZ-induced , 50 mg/kg I.P.), insulin treated diabetic ; (received 0.75 IU/ 100g body weight daily, S.C; for 4 weeks) , EPO treated diabetic; (received EPIAO® S.C , 200 I.U/Kg, 3 times weekly, day after day for 4 weeks),and insulin and EPO treated diabetic groups. At the end of the experiments, fasting blood glucose, insulin levels, lipid profile, contractile changes in soleus muscle and glucose transporter 4 (GLUT4) expression in soleus muscle were evaluated. Results: All biochemical parameters were improved in the group treated with insulin or EPO with greater improvement in insulin treated group. The greatest improvement was in the group treated with combined insulin and EPO. Contractile function of soleus muscle in diabetic group showed significant decrease in muscle tension either before or after fatigue, significant decrease in time taken to reach complete fatigue, significant increase in time taken to reach peak and in time taken to relax to 50% when compared with normal group. All parameters were improved in insulin treated and EPO treated groups, with greater improvement in insulin treated group. The greatest improvement was in combined insulin and EPO treated group. The reduced GLUT 4 expression in diabetic soleus muscle was significantly increased in insulin treated group as compared to EPO treated group, however combined EPO and insulin treated group showed greater increase in GLUT4 expression. Conclusion: The present results showed that, EPO injection improved hyperglycemia, hypoinsulinemia, hyperlipidemia, and skeletal muscle changes observed in STZ-induced diabetes in rats. Therefore, EPO could be beneficial in managing diabetic disorders and the application of EPO in treatment of diabetes can be considered.